Mieloma múltiplo com R-ISS estágio 3 — ISS-3 (β2M ≥5,5) PLUS LDH acima de ULN PLUS alto risco...
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
| ID | RF-R-ISS-3-HIGH-RISK |
|---|---|
| Tipo | Sinal de alerta |
| Estado | reviewed 2026-04-27 | pending_clinical_signoff |
| Doenças | DIS-MM |
| Fontes | SRC-ESMO-MM-2023 SRC-NCCN-MM-2025 |
Origem da bandeira vermelha
| Definição | Multiple myeloma with R-ISS stage 3 — ISS-3 (β2M ≥5.5) PLUS LDH above ULN PLUS high-risk cytogenetics by FISH (any of t(4;14), t(14;16), del(17p)) — most aggressive presentation; supports four-drug D-VRd induction + ASCT (eligible) or D-Rd intensification (unfit) + maintenance |
|---|---|
| Direcção clínica | intensificar |
| Categoria | risco-ponto |
| Algoritmo de deslocamentos | ALGO-MM-1L |
Lógica de Desencadeamento
{
"all_of": [
{
"comparator": ">=",
"finding": "beta2_microglobulin_mg_per_l",
"threshold": 5.5
},
{
"finding": "ldh_above_uln",
"value": true
},
{
"any_of": [
{
"finding": "mm_high_risk_cytogenetics",
"value": true
},
{
"finding": "fish_t_4_14",
"value": true
},
{
"finding": "fish_t_14_16",
"value": true
},
{
"finding": "fish_del_17p",
"value": true
},
{
"finding": "tp53_deletion",
"value": true
}
]
}
],
"type": "composite_score"
}
Notas
R-ISS (Palumbo et al., JCO 2015) refined ISS by adding LDH and FISH cytogenetics: R-ISS-3 = ISS-3 + LDH-high + high-risk FISH. R-ISS-3 median OS ~43 mo pre-daratumumab; modern PERSEUS / IsKia / GRIFFIN show D-VRd benefits across risk groups but absolute outcomes in R-ISS-3 remain inferior — argues for tandem ASCT consideration (StaMINA / EMN02) and aggressive maintenance (lenalidomide +/- daratumumab + ixazomib in selected protocols). Severity `critical` for conflict resolution: this should win over standard de-escalation flags. Co-fires with biomarker-actionability flags for individual cytogenetic hits.
Usado por
Algoritmos
ALGO-MM-1L- ALGO-MM-1L
Sinal de alerta
RF-ISS-3- mieloma múltiplo com ISS estágio 3 — β2-microglobulina ≥5,5 mg/L — apresentação de alto risco;...